ResMed Inc. (RMD)

Compare

223.85

+3.91

+(1.78%)

At close: 4:00:02 PM EDT

223.85

0.00

(0.00%)

After hours: 5:07:01 PM EDT

Morgan Stanley Sees Near-Term Rally Ahead — Here Are 2 Stocks to Bet on It

Markets have proven highly volatile in the first two months of President Trump’s new term of office, as investors are worried about everything from trade and tariff policy to increased inflation to geopolitics. But there are some green lights flashing on the market dashboard. For starters, the prices of some staple goods are coming down – prices are dropping for both gasoline and eggs, for instance – and in the past two weeks, markets have turned back upward. Covering the market situation from M

TipRanks 3 days ago

RMD
+1.78%
RSMDF

CVNA
Jim Cramer On ResMed Inc. (RMD) – “I’m With Mick! ResMed’s Doing Quite Well”

We recently published a list of Jim Cramer Recently Talked About These 12 Companies. In this article, we are going to take a look at where ResMed Inc. (NYSE:RMD stands against other stocks that Jim Cramer discussed recently. Jim Cramer, host of Mad Money, warned investors on Friday that until there is more clarity regarding […]

Insider Monkey 5 days ago

RMD
+1.78%
ResMed initiated with an Overweight at Morgan Stanley

Morgan Stanley analyst David Bailey initiated coverage of ResMed (RMD) with an Overweight rating and $280 price target The company has a market-leading position in the obstructive sleep apnea market and valuations appear attractive at current levels, with a strong balance sheet position and the highest ROIC across the firm’s Australian Healthcare industry sector coverage, the analyst tells investors. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial

TipRanks 11 days ago

RMD
+1.78%
RSMDF
New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer

Largest ever meta-analysis on the long-term benefits of CPAP therapy, published in The Lancet Respiratory Medicine, found that in people with sleep apnea, CPAP therapy lowered the overall chance of dying by 37% and the chance of heart-related death by 55%.SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark meta-analysis in The L

GlobeNewswire 12 days ago

RMD
+1.78%
RSMDF
New Product Launches Benefit GMED Stock Amid Macro Issues

Globus Medical currently awaits a strong cadence of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.

Zacks 13 days ago

GMED

RMD
+1.78%
Why ResMed (RMD) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks 14 days ago

RMD
+1.78%
The Zacks Analyst Blog Highlights NVIDIA, Resmed, GE HealthCare and Medtronic

NVIDIA, Resmed, GE HealthCare and Medtronic are part of the Zacks top Analyst Blog.

Zacks 18 days ago

NVDA

MDT

RMD
+1.78%
NVIDIA's AI Speeds Up MedTech's Digital Boom: 3 Stocks in Focus

RMD, GEHC and MDT are expected to thrive as NVIDIA and other AI leaders' MedTech ventures accelerate digital adoption within the space.

Zacks 19 days ago

NVDA

MDT

RMD
+1.78%
RMD Stock Likely to Benefit From the New Brand Evolution Strategy

In another major brand update, Resmed is likely to unify all the brands under one identity.

Zacks 19 days ago

RMD
+1.78%
CAH
Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology Revolution

Brand Evolution Unites Brands Under One Resmed Identity to Make Better Sleep and Breathing Health More Accessible to EveryoneSAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a comprehensive brand evolution designed to unify its brand portfolio to serve more people and healthcare providers worldwide and reflect growing direct to consumer engagement. For 35

GlobeNewswire 20 days ago

RMD
+1.78%
RSMDF
Patient Monitoring Stocks Q4 Results: Benchmarking ResMed (NYSE:RMD)

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how ResMed (NYSE:RMD) and the rest of the patient monitoring stocks fared in Q4.

StockStory 20 days ago

RMD
+1.78%
DXCM

IRTC
ResMed Among Top Stocks For Recent And Long-Term Profit Growth

A Relative Strength Rating upgrade for ResMed shows improving technical performance. Will it continue?

Investor's Business Daily 21 days ago

RMD
+1.78%
RSMDF
VEEV Stock Gains Following Latest Availability of HCP Access Data

Veeva Systems aims to provide immediate value for commercial operations and data analytics teams via CRM Pulse, which provides quarterly HCP access data.

Zacks 24 days ago

VEEV

RMD
+1.78%
CAH
Is it Worth Adding ResMed Stock to Your Portfolio Now?

Robust Mask and Device sales bode well for ResMed. Meanwhile, the increasing debt burden adds to the worry.

Zacks 24 days ago

RMD
+1.78%
CAH

BSX
Zacks.com featured highlights include Taiwan, Tapestry, ABM Industries, Vertiv and ResMed

Taiwan, Tapestry, ABM Industries, Vertiv and ResMed have been highlighted in this Screen of The Week article.

Zacks 25 days ago

ABM

RMD
+1.78%
TPR
5 Best Dividend Growth Stocks to Buy Amid Trade War Fears

Investors searching for safe and consistent income amid global trade war fears. Dividend growth stocks like TSM, TPR, ABM, VRT and RMD are solid choices.

Zacks 26 days ago

^GSPC

VRT

TPR
ResMed Stock Climbs 25.6% in a Year: What's Driving the Rally?

RMD outperforms the industry and the S&P 500 composite due to its success with the cloud-connected AirSense platform.

Zacks 26 days ago

RMD
+1.78%
CAH
VEEV Stock Falls Despite Latest Announcement to Enable AI Innovation

Veeva Systems aims to enable advanced automation, including AI, for the life sciences industry via innovative technology and deep applications on the Veeva Vault Platform.

Zacks 27 days ago

VEEV

RMD
+1.78%
BSX
2 Reasons to Like RMD and 1 to Stay Skeptical

Since September 2024, ResMed has been in a holding pattern, posting a small loss of 4.8% while floating around $233.10. The stock also fell short of the S&P 500’s 6.2% gain during that period.

StockStory 27 days ago

RMD
+1.78%
Integra Q4 Earnings Beat Estimates, Revenues Rise Y/Y, Stock Up

IART delivers better-than-expected earnings in the fourth quarter of 2024.

Zacks 28 days ago

IART

RMD
+1.78%
CAH

Performance Overview

Return	RMD	S&P 500 (^GSPC)
YTD	-1.90%	-4.59%
1-Year	+14.06%	+6.80%
3-Year	-5.14%	+23.87%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

ResMed Inc. (RMD)

Morgan Stanley Sees Near-Term Rally Ahead — Here Are 2 Stocks to Bet on It

Jim Cramer On ResMed Inc. (RMD) – “I’m With Mick! ResMed’s Doing Quite Well”

ResMed initiated with an Overweight at Morgan Stanley

New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer

New Product Launches Benefit GMED Stock Amid Macro Issues

Why ResMed (RMD) is a Top Growth Stock for the Long-Term

The Zacks Analyst Blog Highlights NVIDIA, Resmed, GE HealthCare and Medtronic

NVIDIA's AI Speeds Up MedTech's Digital Boom: 3 Stocks in Focus

RMD Stock Likely to Benefit From the New Brand Evolution Strategy

Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology Revolution

Patient Monitoring Stocks Q4 Results: Benchmarking ResMed (NYSE:RMD)

ResMed Among Top Stocks For Recent And Long-Term Profit Growth

VEEV Stock Gains Following Latest Availability of HCP Access Data

Is it Worth Adding ResMed Stock to Your Portfolio Now?

Zacks.com featured highlights include Taiwan, Tapestry, ABM Industries, Vertiv and ResMed

5 Best Dividend Growth Stocks to Buy Amid Trade War Fears

ResMed Stock Climbs 25.6% in a Year: What's Driving the Rally?

VEEV Stock Falls Despite Latest Announcement to Enable AI Innovation

2 Reasons to Like RMD and 1 to Stay Skeptical

Integra Q4 Earnings Beat Estimates, Revenues Rise Y/Y, Stock Up

Performance Overview